Chardan Capital downgraded its price objective for Iovance Biotherapeutics, which trades on the Nasdaq stock exchange.
1 report, 1 independent
Updated Aug 27
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Chardan Capital downgraded its price objective for Iovance Biotherapeutics, which trades on the Nasdaq stock exchange.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Iovance Biotherapeutics
American biopharmaceutical startup
Nothing else this week.